UNASSIGNED:前列腺动脉栓塞术(PAE)是良性前列腺增生(BPH)患者下尿路梗阻和血尿的有效微创治疗方法。本研究旨在评估载药物表柔比星珠子经动脉前列腺动脉化疗栓塞(DEB-PACE)治疗晚期前列腺癌(PC)并下尿路梗阻或血尿的安全性和短期疗效。
UNASSIGNED:回顾性纳入了2020年8月至2022年2月接受DEB-PACE治疗的8例晚期PC患者。患者随访1周,DEB-PACE术后1、3、6和12个月。前列腺动脉的起源,技术上的成功,临床成功率,留置导尿管的持续时间,国际前列腺症状评分(IPSS)QoL评分(生活质量),前列腺体积(PV),记录前列腺特异性抗原(PSA)水平和并发症.短期疗效(IPSS的变化,分析了从基线到3个月的PV和QoL值)。
未经证实:8例患者中有17条前列腺动脉,主要起源于阴部内动脉(11/17,64.7%),技术成功率为100%。治疗后,8例患者下尿道梗阻症状明显改善,PV,IPSS和QoL水平显著降低。平均1周内成功拔除导管,2例血尿在5天内消失。临床成功率为100%。术后1个月,平均PV减少为30.28±6.963cm3(P=0.0457),平均IPSS降低21.13±2.887分(P=0.0042),平均生活质量下降为3.75±0.366分(P=0.006).术后3个月,平均PV减少为46.14±8.906cm3(P=0.0112),平均IPSS降低24.5±2.398分(P=0.0003),平均QoL下降4.25±0.25分(P=0.0003).所有患者均未发生严重并发症。
UNASSIGNED:DEB-PACE是一种有前途的治疗下尿路梗阻或血尿的晚期PC的方法。然而,DEB-PACE用于高级PC的有效性和安全性需要通过前瞻性大样本随机对照研究来验证.
UNASSIGNED: Prostatic arterial embolization (PAE) is an effective minimally invasive treatment for lower urinary tract obstruction and hematuria in patients with benign prostatic hyperplasia (BPH). This study was aim to evaluate the safety and short-term efficacy of drug epirubicin-loaded beads transarterial prostatic arterial chemoembolization (DEB-PACE) for the treatment of advanced prostate cancer (PC) with lower urinary tract obstruction or hematuria.
UNASSIGNED: A total of 8 patients with advanced PC undergoing DEB-PACE from August 2020 to February 2022 were retrospectively enrolled. The patients were followed up at 1 week, 1, 3, 6 and 12 months after DEB-PACE. The origin of prostatic arteries, technical success, clinical success rate, duration of the indwelling urinary catheter, International Prostate Symptom Score (IPSS), QoL score (quality of life), prostate volume (PV), prostate-specific antigen (PSA) level and complications were recorded. The short-term efficacy (changes in IPSS, PV and QoL value from baseline to 3 months) were analysed.
UNASSIGNED: There were 17 prostatic arteries in 8 patients, which mainly originated from internal pudendal artery (11/17, 64.7%), the technical success rate is 100%. After treatment, the symptoms of lower urethral obstruction in 8 patients were significantly improved that PSA, PV, IPSS and QoL level were significantly reduced. The catheter was successfully removed within 1 week on average, and 2 patients with hematuria disappeared within 5 days. The clinical success rate is 100%. At 1 month postoperatively, mean PV reduction was 30.28±6.963 cm3 (P=0.0457), mean IPSS reduction was 21.13±2.887 points (P=0.0042), mean QoL reduction was 3.75±0.366 points (P=0.006). At 3 months postoperatively, mean PV reduction was 46.14±8.906 cm3 (P=0.0112), mean IPSS reduction was 24.5±2.398 points (P=0.0003), mean QoL reduction was 4.25±0.25 points (P=0.0003). There were no serious complications occurred in all patients.
UNASSIGNED: DEB-PACE is a promising treatment for advanced PC with lower urinary tract obstruction or hematuria. However, the efficacy and safety of DEB-PACE for advanced PC is needed to validated by prospective large sample randomized controlled study.